XPO1抑制剂塞利尼索（KPT-330）对非血液系统癌症的疗效：一项全面综述。
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
作者信息
Landes Jennifer R, Moore Stephen A, Bartley Brooke R, Doan Hung Q, Rady Peter L, Tyring Stephen K
机构信息
Department of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.308, Houston, TX, 77070, USA.
Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Cancer Res Clin Oncol. 2023 May;149(5):2139-2155. doi: 10.1007/s00432-022-04247-z. Epub 2022 Aug 8.
PURPOSE
Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor's efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors.
METHODS
Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials.
RESULTS
This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies.
CONCLUSION
Further clinical investigation of selinexor treatment for solid malignancies is warranted.
目的
塞利尼索是一种新型的XPO1抑制剂，可抑制肿瘤抑制蛋白和癌蛋白mRNA的输出，导致癌细胞的细胞周期停滞和凋亡。虽然塞利尼索目前已获美国食品药品监督管理局（FDA）批准用于治疗多发性骨髓瘤，但令人信服的临床前和早期临床研究表明，塞利尼索在治疗血液系统和非血液系统恶性肿瘤方面具有疗效，包括肉瘤、胃癌、膀胱癌、前列腺癌、乳腺癌、卵巢癌、皮肤癌、肺癌和脑癌。目前对塞利尼索的综述主要强调其在血液系统恶性肿瘤中的应用；然而，本综述旨在总结塞利尼索治疗实体瘤的最新证据。
方法
在PubMed和Karyopharm Therapeutics网站上对塞利尼索以及非血液系统恶性肿瘤的临床前和临床试验进行相关文献检索。
结果
本综述提供的证据表明，塞利尼索在非血液系统恶性肿瘤中单独使用或与其他抗癌药物联合使用是一种有前景的药物。
结论
有必要对塞利尼索治疗实体恶性肿瘤进行进一步的临床研究。
Zotero 插件